Analyst consensus rating
Cellectar Biosciences Analyst Rating: Strong Buy
CLRB is rated Strong Buy by 4 analysts with a $11.50 target. As of 2026-08-24.
Direct answer
Cellectar Biosciences's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.50.
Forecast evidence checked August 24, 2026.
Get free Cellectar Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.59
- Average price target
- $11.50
- High price target
- $15.00
- Low price target
- $10.00
- Low target gap
- +286.1%
- Target upside
- +344%
- High target gap
- +479.2%
- Target range width
- 193.1%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cellectar Biosciences?
Cellectar Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $11.50.
How far are Cellectar Biosciences's low and high targets from the recorded price?
The low target implies +286.1%, while the high target implies +479.2%.
How many analysts are included in Cellectar Biosciences's consensus?
The verified consensus includes 4 analysts.
How is Cellectar Biosciences's target upside or downside calculated?
The average target of $11.50 is divided by the recorded price of $2.59, then one is subtracted to produce +344%. This does not guarantee a future return.
When was Cellectar Biosciences's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.